Bristol-Myers Squibb says US regulators have finally given their blessing for its $74bn takeover of Celgene, setting up a completion of the deal on 20 November.
BMS to acquire Celgene for $74 billion in biggest-ever pharma deal
The approval by the Federal Trade Commission comes more than ten months after BMS and Celgene first broke the news of the planned merger, and several months after an attempt to scupper the deal by disgruntled investors was defeated.
The deal will create a combined company with annual revenues in excess of $34bn, making it the sector’s fourth biggest firm behind Pfizer, Novartis and Roche.(Más)
Entradas
No hay comentarios:
Publicar un comentario